Method for treating vitiligo with a prostaglandin analogue
AssigneeAgila Specialities Pvt. Ltd.
InventorsRajeev JAIN, Tarun Narang, Satya Srinivas Chetlapalli
Life of this patent
Estimating the term…
Abstract
A method of stimulating melanogenesis in a skin surface of a patient, by treating the skin surface with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier. The topical formulation may be a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, or a transdermal patch. The dermatologically acceptable carrier may contain an oily carrier or an aqueous carrier.
Claims23
1) A method of stimulating pigmentation in a depigmented skin region of a patient, comprising treating said depigmented skin region with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier,
- said depigmented skin region having fewer melanocytes per square centimeter than a nondepigmented skin region of said patient, said depigmented skin region being surrounded by or adjacent to said nondepigmented skin region.
9) A method of treating a patient suffering from segmental or focal vitiligo, comprising treating a depigmented skin surface of said patient with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier, said treating step being carried out at regular intervals until repigmentation of said depigmented skin surface is complete.
10) A method of treating a patient suffering from generalized vitiligo, comprising a first step of treating a depigmented skin surface of said patient with a topical formulation comprising a first amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier, said first amount being effective to promote repigmentation, wherein said first step is carried out at regular intervals until repigmentation of said depigmented skin surface is complete.
12) A method of treating localized skin depigmentation in a patient, comprising treating depigmented skin of said patient by applying thereto a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier.
21) A method of treating a patient suffering from vitiliginous lesions on the face, the neck, or both the face and the neck, said method comprising:
- treating said lesions with a topical formulation comprising a first amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier, said first amount being effective to promote repigmentation of said lesions;
- wherein said treating step is carried out at regular intervals until repigmentation of said lesions is complete.
22) A method of treating localized skin depigmentation in a patient, comprising treating depigmented skin of said patient by applying thereto a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier;
- said method further comprising a step of treating said depigmented skin with a composition selected from the group consisting of pseudocatalase cream, dermabest gel, V-Tar, tacrolimus, pimecrolimus, steroids, psoralen, methoxsalen, trioxsalen, glatiramer acetate, and topical calcineurin inhibitors.
Dependencies are inferred from the claim text.